Loading...

Qualigen Therapeutics, Inc.

QLGN•NASDAQ
Healthcare
Biotechnology
$3.41
$-0.00(-0.09%)

Qualigen Therapeutics, Inc. (QLGN) Stock Overview

Explore Qualigen Therapeutics, Inc.’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

B

Score: 65.5/100

Key Financials

Market Cap2.4M
P/E Ratio-0.16
EPS (TTM)$-17.27
ROE2.61%
Fundamental Analysis

AI Price Forecasts

1 Week$3.99
1 Month$4.66
3 Months$0.00
1 Year Target$3.13

QLGN Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Qualigen Therapeutics, Inc. (QLGN) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

Our forecasting models predict significant price movements, with a 12-month target of $3.13.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -0.16 and a market capitalization of 2.4M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Stats data is not available for QLGNStats details for QLGN are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Analyst Recommendations data is not available for QLGNAnalyst Recommendations details for QLGN are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

Qualigen Therapeutics, Inc., a biotechnology company, develops novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a rapid diagnostic testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, a DNA coated gold nanoparticle cancer drug candidate that targets various cancers; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and STARS blood cleansing system, a DNA/RNA-based treatment device that removes tumor-produced compounds and viruses from a patient's blood. Qualigen Therapeutics, Inc. was founded in 1996 and is based in Carlsbad, California.

CEO

Kevin A. Richardson II

Employees

4

Headquarters

2042 Corte Del Nogal, Carlsbad, CA

Founded

2015

Frequently Asked Questions

;